Evidence suggests that SGLT2 inhibitors not only lower the renal glucose threshold and improve volume status to alleviate heart failure but also reduce the risk of cardiovascular events, as confirmed in the DAPA-CKD [24], EMPA-KIDNEY [25], and CREDENCE [26] trials. This evidence concerns the gene SLC5A2 and chronic kidney disease.